{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient changed to a 3rd line regimen which consisted of Carboplatin (AUC5), pemetrexed, atezolizumab, bevacizumab.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0007129",
              "dosage": "AUC5",
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1634849",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C4049449",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1263442",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Three months later 18F-FDG PET/CT showed excellent response with complete metabolic remission and no evidence of residual or new FDG-avid malignant or metastatic disease.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorodeoxyglucose F-18-PET/CT",
              "body_part": "entire body",
              "modality": "PET/CT",
              "finding": "complete metabolic remission",
              "impression": "no evidence of residual or new FDG-avid malignant or metastatic disease",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Patient commenced treatment with crizotinib, where the patient showed a positive response, achieving complete metabolic remission.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0982459",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "A year later the patient underwent a 18F-FDG PET/CT scan for the evaluation of disease reoccurrence due to the development of abdominal symptoms.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorodeoxyglucose F-18 PET/CT",
              "body_part": "abdomen",
              "modality": "PET",
              "finding": "disease reoccurrence",
              "impression": "evaluation of disease reoccurrence",
              "date": null
            },
            {
              "type": "Fluorodeoxyglucose F-18 PET/CT",
              "body_part": "abdomen",
              "modality": "CT",
              "finding": "disease reoccurrence",
              "impression": "evaluation of disease reoccurrence",
              "date": null
            }
          ],
          "HPI": [
            {
              "summary": "development of abdominal symptoms",
              "duration": null,
              "onset": null,
              "progression": "unknown",
              "associated_symptoms": [
                "Abdominal symptom"
              ],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "18F-FDG PET/CT showed ascites in the abdomen and pelvis with heterogenous low-grade FDG uptake and fat stranding, raising the possibility of peritoneal metastatic disease. There was a new large, intensely FDG-avid irregularly shaped soft tissue mass between the rectum and urinary bladder in keeping with a large peritoneal deposit.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography/computed tomography",
              "body_part": "abdomen and pelvis",
              "modality": "PET",
              "finding": "ascites with heterogenous low-grade FDG uptake and fat stranding, raising the possibility of peritoneal metastatic disease. There was a new large, intensely FDG-avid irregularly shaped soft tissue mass between the rectum and urinary bladder in keeping with a large peritoneal deposit."
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Biopsy confirmed Peritoneal Carcinomatosis (PC).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C1614668",
              "label": "Peritoneal Carcinomatosis",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "Biopsy",
              "approach": "percutaneous",
              "location": "Peritoneal cavity",
              "outcome": "positive"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Treatment was changed to Lorlatinib.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1608951",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "Post-treatment 18F-FDG PET/CT showed complete metabolic resolution of the ascites and peritoneal disease. No FDG-avid local lung recurrence or other metastasis indicated complete metabolic remission.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorodeoxyglucose F-18",
              "body_part": "peritoneum",
              "modality": "PET/CT",
              "finding": "complete metabolic resolution of the ascites and peritoneal disease",
              "impression": "complete metabolic remission"
            },
            {
              "type": "Fluorodeoxyglucose F-18",
              "body_part": "lung",
              "modality": "PET/CT",
              "finding": "no FDG-avid local lung recurrence or other metastasis",
              "impression": "complete metabolic remission"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Nine months later the patient developed recurrent significant abdominal bloating and pain.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Recurrent significant abdominal bloating and pain",
              "duration": "9 months",
              "onset": "9 months prior",
              "progression": "recurrent",
              "associated_symptoms": [
                "Abdominal bloating",
                "Pain"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "Patient underwent a 18F-FDG PET/CT scan, which showed findings consistent with recurrent peritoneal disease.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorodeoxyglucose F-18",
              "body_part": "peritoneum",
              "modality": "PET/CT",
              "finding": "recurrent peritoneal disease"
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 10,
        "content": "18F-FDG PET/CT showed no evidence of FDG-avid local lung carcinoma recurrence or extra peritoneal spread. Pre-therapy maximum intensity projection (MIP) image showing recurrence in the mid abdomen.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography/computed tomography",
              "body_part": "lung",
              "modality": "PET",
              "finding": "no evidence of FDG-avid local lung carcinoma recurrence or extra peritoneal spread"
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 11,
        "content": "Pre-therapy transverse section of PET/CT showed peritoneal recurrence in the mid abdomen and ascites.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Peritoneal recurrence",
              "body_part": "Peritoneum",
              "modality": "PET/CT",
              "finding": "Peritoneal recurrence in the mid abdomen",
              "date": null
            },
            {
              "type": "Ascites",
              "body_part": "Abdomen",
              "modality": "PET/CT",
              "finding": "Ascites",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N13",
      "label": "Step 13",
      "customData": {
        "node_id": "M",
        "node_step_index": 12,
        "content": "Patient had further peritoneal recurrence in the mid abdomen.",
        "clinical_data": {}
      }
    },
    {
      "id": "N14",
      "label": "Step 14",
      "customData": {
        "node_id": "N",
        "node_step_index": 13,
        "content": "Complete metabolic response of the peritoneal disease after third line of treatment.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C56",
              "label": "Malignant neoplasm of ovary",
              "status": "resolved"
            }
          ]
        }
      }
    },
    {
      "id": "N15",
      "label": "Step 15",
      "customData": {
        "node_id": "O",
        "node_step_index": 14,
        "content": "Pre- and post-treatment fluorodeoxyglucose positron emission tomography (PET) at first presentation showing complete metabolic response of primary right lung, nodal metastasis and left pleural effusion.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Fluorodeoxyglucose positron emission tomography",
              "body_part": "lung",
              "modality": "PET",
              "finding": "complete metabolic response of primary right lung, nodal metastasis and left pleural effusion",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N16",
      "label": "Step 16",
      "customData": {
        "node_id": "P",
        "node_step_index": 15,
        "content": "Pre-therapy maximum intensity projection (MIP) image showing right lung primary tumor and mediastinal nodal metastasis.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Maximum Intensity Projection Image",
              "body_part": "Lung",
              "modality": "other",
              "finding": "Right lung primary tumor and mediastinal nodal metastasis",
              "date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Transition from 3rd line regimen to PET/CT scan showing excellent response.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0007129",
            "C1634849",
            "C4049449",
            "C1263442"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Transition from complete metabolic remission to treatment with crizotinib and subsequent complete metabolic remission.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0982459"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Transition from crizotinib treatment to development of abdominal symptoms and evaluation of disease reoccurrence via 18F-FDG PET/CT scan.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Transition from evaluation of disease reoccurrence to 18F-FDG PET/CT showing ascites and potential peritoneal metastatic disease.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Transition from imaging findings suggestive of peritoneal metastatic disease to biopsy confirmation of Peritoneal Carcinomatosis (PC).",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Transition from diagnosis of Peritoneal Carcinomatosis to treatment change to Lorlatinib.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1608951"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Transition from Lorlatinib treatment to post-treatment 18F-FDG PET/CT showing complete metabolic resolution of ascites and peritoneal disease.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "resolution",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Transition from complete metabolic resolution to development of recurrent significant abdominal bloating and pain after nine months.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true
      }
    }
  ]
}